Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.36660/abc.20200273 http://scihub22266oqcxt.onion/10.36660/abc.20200273 32491073!8386999!32491073     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arq+Bras+Cardiol 2020 ; 114 (5): 817-822 Nephropedia Template TP {{tp|p=32491073|t=2020. O Efeito da Doenca de Coronavirus 2019 nas Doencas Cardiovasculares |pdf=|usr=}}{{32491073}} gab.com Text O Efeito da Doenca de Coronavirus 2019 nas Doencas Cardiovasculares JO: Arq Bras Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32491073 #FOAvip Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19. Twit Text FOAVip O Efeito da Doenca de Coronavirus 2019 nas Doencas Cardiovasculares ????Arq Bras Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32491073 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32491073 #FOAvip English Wikipedia <ref>{{Cite pmid|32491073}}</ref> O Efeito da Doenca de Coronavirus 2019 nas Doencas Cardiovasculares #MMPMID32491073 Askin L; Tanriverdi O; Askin HS Arq Bras Cardiol 2020[Jun]; 114 (5): 817-822 PMID32491073show ga Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19. |*Betacoronavirus[MESH] |Angiotensin Receptor Antagonists/metabolism[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |Antirheumatic Agents/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19[MESH] |Cardiovascular Diseases/enzymology/*epidemiology/mortality[MESH] |China/epidemiology[MESH] |Chloroquine/therapeutic use[MESH] |Comorbidity[MESH] |Coronavirus Infections/drug therapy/enzymology/*epidemiology/mortality[MESH] |Humans[MESH] |Hypertension/enzymology/epidemiology[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/metabolism[MESH] |Pneumonia, Viral/drug therapy/enzymology/*epidemiology/mortality[MESH]O Efeito da Doenca de Coronavirus 2019 nas Doencas Cardiovasculares (epmc).pdf DeepDyve Pubget Overpricing